TY - JOUR
T1 - Standardising definitions, endpoints, and reporting parameters for clinical studies of stereotactic body radiation therapy in bone metastases
T2 - An international Delphi consensus
AU - Lee, Shing Fung
AU - Wong, Henry C.Y.
AU - Oldenburger, Eva
AU - Raman, Srinivas
AU - Marta, Gustavo N.
AU - Chan, Adrian W.
AU - Rades, Dirk
AU - van der Linden, Yvette M.
AU - van der Velden, Joanne M.
AU - Nguyen, Quynh Nhu
AU - Choi, J. Isabelle
AU - Hircock, Caroline
AU - Doccioli, Chiara
AU - Cosma, Claudia
AU - Caini, Saverio
AU - Rembielak, Agata
AU - Vassiliou, Vassilios
AU - Bonomo, Pierluigi
AU - Alcorn, Sara
AU - Johnstone, Candice
AU - Simone, Charles B.
AU - Hoskin, Peter J.
AU - Chow, Edward
AU - Ryu, Samuel
N1 - Publisher Copyright:
© 2026 Elsevier Ltd.
PY - 2026/6/18
Y1 - 2026/6/18
N2 - Background Stereotactic body radiation therapy (SBRT) is increasingly used for bone metastases, but inconsistent endpoint definitions and reporting hinder evidence synthesis and clinical application. This study aimed to establish international consensus recommendations for standardised endpoints, definitions, and reporting parameters in SBRT studies for bone metastases. Methods A systematic review of prospective SBRT studies (2014–2024) informed a three-round modified Delphi consensus process conducted from 2024 to 2025. Consensus was predefined as at least 75% agreement. Candidate items were refined through iterative online surveys, qualitative feedback, and a final prioritisation vote by an international multidisciplinary expert panel. Results Of 114 invited experts, 82 from 20 countries participated in at least one Delphi round. Review of 58 prospective studies showed substantial variability in endpoint definitions, pain and toxicity assessment, radiological response criteria, and timing of outcome evaluation. The panel endorsed 46 reporting items (41 required, 5 recommended) and prioritised core endpoint sets across three clinical contexts: oligometastatic, oligoprogressive, and asymptomatic high-risk bone metastases. Strong consensus was reached for definitions of vertebral compression fracture (92%), time to salvage local therapy (93%), duration of pain response (92%), and time to local progression (90%); pain flare achieved 89% agreement. A revised clinical response framework (C-BRAC), introducing a stable disease category, achieved 91% agreement and was recommended for exploratory use alongside existing criteria. Conclusions These recommendations provide a structured framework for designing and reporting SBRT studies in bone metastases and may improve consistency, comparability, and future guideline development.
AB - Background Stereotactic body radiation therapy (SBRT) is increasingly used for bone metastases, but inconsistent endpoint definitions and reporting hinder evidence synthesis and clinical application. This study aimed to establish international consensus recommendations for standardised endpoints, definitions, and reporting parameters in SBRT studies for bone metastases. Methods A systematic review of prospective SBRT studies (2014–2024) informed a three-round modified Delphi consensus process conducted from 2024 to 2025. Consensus was predefined as at least 75% agreement. Candidate items were refined through iterative online surveys, qualitative feedback, and a final prioritisation vote by an international multidisciplinary expert panel. Results Of 114 invited experts, 82 from 20 countries participated in at least one Delphi round. Review of 58 prospective studies showed substantial variability in endpoint definitions, pain and toxicity assessment, radiological response criteria, and timing of outcome evaluation. The panel endorsed 46 reporting items (41 required, 5 recommended) and prioritised core endpoint sets across three clinical contexts: oligometastatic, oligoprogressive, and asymptomatic high-risk bone metastases. Strong consensus was reached for definitions of vertebral compression fracture (92%), time to salvage local therapy (93%), duration of pain response (92%), and time to local progression (90%); pain flare achieved 89% agreement. A revised clinical response framework (C-BRAC), introducing a stable disease category, achieved 91% agreement and was recommended for exploratory use alongside existing criteria. Conclusions These recommendations provide a structured framework for designing and reporting SBRT studies in bone metastases and may improve consistency, comparability, and future guideline development.
KW - Bone metastases
KW - Clinical trial reporting
KW - Delphi consensus
KW - Endpoints
KW - Standardisation
KW - Stereotactic body radiation therapy
UR - https://www.scopus.com/pages/publications/105038469581
U2 - 10.1016/j.ejca.2026.116783
DO - 10.1016/j.ejca.2026.116783
M3 - Review article
C2 - 42114408
AN - SCOPUS:105038469581
SN - 0959-8049
VL - 241
JO - European Journal of Cancer
JF - European Journal of Cancer
M1 - 116783
ER -